CompletedPhase 2

Effect of Rutin on Inflammation Pathways in Ulcerative Colitis Patients

Egypt60 participantsStarted 2025-02-22

Plain-language summary

This study evaluates the therapeutic role of Rutin (a plant-derived flavonoid) in reducing the severity of Ulcerative Colitis (UC). The study investigates whether Rutin can decrease intestinal inflammation and improve clinical symptoms by inhibiting the NLRP3 inflammasome signaling pathway, which is activated by oxidative stress in the colon.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of UC confirmed by endoscopy/histology. * Age 18 to 65 years. Exclusion Criteria: * Pregnancy or breastfeeding. * Known hypersensitivity to Rutin. * Presence of other serious systemic diseases (e.g., malignancy, severe hepatic or renal failure).

What they're measuring

Success Rate of Clinical Improvement

Timeframe: Day 30 (End of treatment)

Trial details

NCT IDNCT07370220

SponsorBenha University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-05-25

View on ClinicalTrials.gov More Ulcerative Colitis trials